Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with initial intracranial control results that appear encouraging. ja.ma/4fAaPDY Kamran Ahmed Moffitt Cancer Center

Weighing the Options: Considerations for Adjuvant CDK4/6 Inhibitor Selection in HR+ Breast Cancer Jason A. Mouabbi MD @mdandersonnews #bcsm #oncology onclive.com/view/weighing-…

Starting Now: Lobular Breast Carcinoma Moderated by: Eric Winer, MD #DAVABreast

Dr. Jason Mouabbi discusses how efforts to leverage targets implicated in CDK 4/6 resistance in HR positive, HER2 negative breast cancer have resulted in the development of several classes of endocrine therapies: brnw.ch/21wM2WO Jason A. Mouabbi MD #BreastCancer #EndCancer

What an incredible presentation by the amazing Tess O'Meara, MD, MHS at DAVA Oncology! 🌟 Can't wait to see this superstar shine on many more stages in the future! #bcsm #EndCancer #RisingStar

We had an amazing time in beautiful 🏝️ #Kona with the incredible Heather McArthur, MD, MPH at DAVA Oncology! One of the highlights was meeting one of my new favorite MSL, Matthew Spencer from Menarini Stemline. Rebecca Shatsky, MD, where have you been hiding this gem 💎?!

The DAVA Oncology 2024 #breastcancer Summit in beautiful 🏝️ #Kona, #Hawaii, was truly exceptional! 🌺 IMO, it was the most special #breastcancer meeting, where junior faculty had the unique opportunity to meet, network, and collaborate with the giants of breast oncology. Huge applause

DESTINY-Breast06 Redefines Treatment Paradigms, Calls Necessity of HER2 Testing for T-DXd into Question in HR+ Breast Cancer Jason A. Mouabbi MD @mdandersonnews #bcsm #oncology #MedTwitter onclive.com/view/destiny-b…

A new generation of clinical trials focused on patient care is emerging. Join our wonderful panel of experts including Janet woodcock and Clifton Leaf and hear more about the ground-breaking work done in the I-SPY 2.2 trial at our press conference held on September 16th, 2024.

Neoadjuvant ICIs in Early BC: meta-analysis ✅️Neoadj ICIs increase pCR rates in both TNBC and HR+/HER2- (PDL1+) subtypes ✅️Neoadj ICI is associated with EFS regardless of pCR status ❗️Adjuvant ICI provides no additional benefit 🔍The results of OptimICE-PCR will provide

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm

We're thrilled to have the #Superstar Fumiko Ladd Chino, MD, FASCO join our exceptional team at MD Anderson Cancer Center! Your expertise and passion are exactly what we need to push the boundaries in our fight to #EndCancer. 👏🏻👏🏻👏🏻 Wendy Woodward MDPhD for adding such a gem to our ranks #EndCancer #bcsm

It is #showtime 🎬🎥 👀Be on the lookout! More to come soon!

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer. Jason A. Mouabbi MD MD Anderson Cancer Center #bcsm onclive.com/view/a-new-wav…

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer. Jason A. Mouabbi MD @mdandersonnews #bcsm #oncology onclive.com/view/weighing-…

Feasibility of breast conserving surgery alone in HER2-positive invasive breast cancer exceptional responders to neoadjuvant systemic therapy sciencedirect.com/science/articl…

Efforts leveraging targets implicated in CDK 4/6 resistance for patients with HR-positive, HER2-negative breast cancer have resulted in the development of several up-and-coming classes of endocrine therapies. Jason A. Mouabbi MD MD Anderson Cancer Center #bcsm onclive.com/view/a-new-wav…

Exciting times ahead in metastatic #BreastCancer care! I believe we are on the verge of monitoring therapy response primarily through #ctDNA, with imaging reserved for when levels rise from baseline. Precision medicine in action! 🎯 #bcsm #EndCancer Oncology Brothers OncoAlert

Congratulations to Heather McArthur, MD, MPH for her podium talk at #ESMO24 and for her impact on breast cancer care in DFW and North Texas!!! cslide.ctimeetingtech.com/esmo2024/atten…

Breast Cancer is not one disease. It is time we approach cancer with personalized treatments that are safe and effective for patients. This is the goal of the RECAST Study: clinicaltrials.ucsf.edu/trial/NCT06075… today.com/video/elle-mac…